Phase 2b Study Findings for an Oral IL-23 Blocker in Psoriasis are Encouraged.

Published Date: 08 Jul 2023

In the FRONTIER 1 study, an investigational IL-23R antagonist significantly outperformed placebo at week 16 in terms of effectiveness in patients with moderate to severe psoriasis across all doses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot